News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BrainStorm Cell Therapeutics Inc. To Present Phase IIa ALS Clinical Trial Data At The Joint Congress Of European Neurology



5/28/2014 10:27:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - May 27, 2014) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting initial results from its Phase IIa ALS trial at the Joint Congress of European Neurology in Istanbul, Turkey, May 31-June 3. BrainStorm's Principal Investigator, Professor Dimitrios Karussis of the Hadassah Medical Center in Jerusalem, will present the interim safety and preliminary efficacy data.

"The clinical observations and interim data of these patients, all of whom received combined intramuscular and intrathecal injections of NurOwn™ cells, were very impressive and appear to reinforce the positive results from BrainStorm's Phase I/II ALS trial," commented Professor Karussis.

The presentation details are as follows:

Title: Analysis of patients with amyotrophic lateral sclerosis (ALS) treated with autologous differentiated mesenchymal stem cells: a phase I/II and IIa clinical trial
Oral Session 2.2: Motor neurone diseases
Date and Time: Sunday, June 1, 2014 16.45 - 18.15

The Joint Congress of European Neurology in Istanbul, Turkey is organized by the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS). At this congress, the European Academy of Neurology (EAN) will be founded, a single society uniting neurologists from all over Europe.

About NurOwn™
NurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into "MSC-NTF" cells. These neuron-supporting cells secrete elevated levels of neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction. The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases. More information about NurOwn™ can be found at http://brainstorm-cell.com/index.php/science-a-technology/-nurown.

About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


Contact
BrainStorm Cell Therapeutics Inc.
(OTCQB: BCLI)
Mr. Chaim Lebovits
President
Phone: +972-3-9236384
info@brainstorm-cell.com

US Investor Contact
LifeSci Advisors, LLC
Michael Rice
Phone: 646-597-6979
mrice@lifesciadvisors.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES